key: cord-0987913-vqpfmfhr
authors: Peled, Yael; Afek, Arnon; Nemet, Ital; Rahav, Galia; Raanani, Ehud; Patel, Jignesh K.; Mandelboim, Michal
title: Fourth BNT162b2 Vaccination Neutralization of Omicron Infection after Heart Transplantation
date: 2022-05-05
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2022.04.014
sha: a34ee1a6cba677694ea833b0bfe9bd17024799bd
doc_id: 987913
cord_uid: vqpfmfhr

We investigated changes in receptor-binding domain IgG and neutralizing antibodies against the omicron and delta variants, vs. the wild-type virus, in response to a fourth BNT162b2 dose in 90 heart transplant (HT) recipients. The fourth dose induced anti-RBD IgG antibodies and a higher neutralization efficiency against the wild-type virus and the variants; however, neutralization efficiency against the omicron variant was lower than that against the delta variant (the latter demonstrating efficacy similar to that against the wild-type virus). Notably, while IgG anti-RBD antibodies were detectable in >80% of the HT recipients, only about half demonstrated neutralization efficiency against the omicron variant. A SARS-CoV-2-specific-T-cell response following the fourth dose was evident in the majority of transplant recipients. Boosting vulnerable groups improves antibody responses (including neutralizing responses) and cellular immunity, but the incomplete immunological response, particularly for omicron, suggests continued preventive measures and optimization of vaccination strategies that elicit strong, and long-lasting immune responses, in this high-risk population, should remain a priority.

The emergence of new SARS-CoV-2 variants of concern (VOCs), particularly the highly transmissible omicron variant, has highlighted the need to improve vaccine-induced immune responses. 1 Currently, the strategy of repeated booster doses is controversial, and data on the efficacy of repeated boosters is limited. This issue is of particular relevance for solid organ transplant recipients, who are vulnerable to worst effects of COVID-19, 2 and for whom ongoing COVID-19 excess deaths are reported, even after the advent of vaccinations and new therapeutics. 3 It has been shown that the vaccine immune paresis that renders transplant patients vulnerable to severe infection, even after vaccination, 4 is further impacted by waning immunity after the third dose of the BNT162b2 vaccine. 1, 5, 6 In addition, the higher mutation frequency in immunocompromised patients 7 The HT recipients (age 57.2±13.8, 69% males, Table) received the fourth BNT162b2 dose 173.4±4.2 days after the third dose. There were no safety concerns. Anti-RBD IgG antibodies were detected in 54 (61.4%) and 71 (80.7%) HT patients before and after the fourth dose, respectively ( Fig. 1A) , with GMTs increasing from 12.5 to 96.9 AU/mL (Fig. 1B) . The fourth dose induced better neutralization of the wild-type virus and the delta and omicron variants, with GMTs increasing from 11.1, 9.4, and 2.9 to 41.9, 38.8, and 10.4, respectively (Fig. 1C) . The percentages of patients demonstrating neutralizing activity against the wild-type virus and the delta and omicron variants increased from 48%, 47%, and 24% to 68% (p<0.01), 66% (p<0.01), and 49% (p<0.01), respectively (Fig. 1D) . Nonetheless, a lower neutralization efficiency of the vaccine against the omicron variant (but not against the delta variant) compared to the wild-type virus was observed after the fourth dose (p<0.001) (Fig. 1E) . The T-cell response was evaluated in a subset of 20 patients; of these, 10 (50%) and 15 (75%) demonstrated COVID-19 specific T-cell immunity before and after the fourth dose, respectively.

The fourth dose induced anti-RBD IgG antibodies and a higher neutralization efficiency against wild-type virus and variants; however, neutralization efficiency against the omicron variant was lower than that against the delta variant (the latter demonstrating efficacy similar to that against the wild-type virus). Notably, while IgG anti-RBD antibodies were detectable in >80% of the HT recipients, only about half demonstrated neutralization efficiency against the omicron variant. The importance of neutralization assays has previously been shown by data indicating a correlation between neutralizing antibodies and symptomatic disease, and this is the first study to report fourth vaccination neutralization of infection with VOCs in this at-risk population.

Our novel findings have immediate implications for vaccination and therapeutic strategies during the ongoing COVID-19 pandemic. The importance of our findings is emphasized by recent concerns regarding the limited efficacy of monoclonal antibodies against the omicron variant, 8, 9 as passive antibody prophylaxis is being considered as an alternative strategy in efforts to protect transplant patients. Until new vaccines, or other strategies, offering better protection against VOCs become available, our data indicate that boosting vulnerable groups improves antibody responses (including neutralizing responses) and cellular immunity, may be an acceptable strategy. Nonetheless, the incomplete immunological response, particularly against the omicron variant, suggests that continued vigilance and preventive measures in this high-risk population should remain a priority. Additional protection against omicron infection and severe disease provided by a fourth dose reported for the general population 10 is encouraging and could translate into a higher benefit for high risk-populations.

Our results should be interpreted with caution. While this study suggests a favorable safety profile, it was not designed to establish the clinical efficacy or the durability of the vaccine-induced immune responses, thus comparison with alternative strategies such as passive antibody prophylaxis cannot be determined. Importantly, continuous assessment and optimization of vaccination strategies that elicit strong, and long-lasting immune responses, aiming to prevent infection and transmission, and prevent severe disease and death, should be thought. Clinical correlation of these data will be needed.

None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.

Serum samples were collected from 90 heart transplant recipients immediately before and 16 days after the fourth dose. Sera were tested for SARS-CoV-2 anti-RBD IgG (Panels A and B) and neutralizing antibodies (Panels C, D, and E). Prevalence of SARS-CoV-2 IgG (A) and quantitation of SARS-CoV-2 IgG (B) before and after the fourth dose are shown. (C) Samples were tested by microneutralization against wild-type virus (blue) and the delta (green) and omicron (red) variants of concern. Dashed lines indicate the cutoff titer. Solid lines and numbers indicate the geometric mean titer, and error bars show the 95% confidence interval. (D) Fraction of individuals showing neutralization above the threshold at

Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine

Covid-19 in recipients of heart and lung transplantation: Learning from experience

Quantifying Excess Deaths Among Solid Organ Transplant Recipients in the COVID-19 Era

COVID-19 infection in solid organ transplant recipients after SARSCoV-2 vaccination

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Omicron variant escapes therapeutic mAbs including recently released Evusheld ®, contrary to eight prior main VOC

Protection by 4th dose of BNT162b2 against Omicron in Israel